



For immediate release

Immunocore and SHIL scoop Genesis Awards 2011

2 December 2011

London, UK – 2 December 2011: Oxford-based cancer therapeutics company Immunocore and Scottish Health Innovations (SHIL) were the winners at the coveted 2011 Genesis Awards, announced at a special Awards Dinner following the conclusion of Genesis 2011.

Harriet Fear, CEO of One Nucleus said that competition was fierce and showed that despite the current economic downturn, there is a wealth of innovation in the UK life sciences sector: "Companies such as Immunocore and SHIL show that innovation is alive and kicking in the UK. One Nucleus wanted to find a way to provide continued practical encouragement and have thus restructured the Genesis Awards. We decided the best way was to reduce the awards to two – BioPharma Innovation and Medtech Innovation – and give them real value. Thus the winners each receive £25,000 worth of pledged benefits from leading One Nucleus members in key areas along the company development chain – a wide range of pivotal support ranging from patenting to regulatory filing and access to potential partners and investors."

Immunocore www.immunocore.com is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of cancer and infectious disease. Its world-leading T cell receptor technology exploits the power of the body's own immune system to find and kill diseased cells and the judges recognised the significant progress the company has made over the last year with its lead product for treating melanoma, one of the most rapidly growing cancer indications worldwide.

Glasgow-based Scottish Health Innovations www.shil.co.uk won the Medtech Innovation award for working to commercialise iPAM, a collaborative project between Dr Alastair Cozens, Consultant in Rehabilitation Medicine at Woodend Hospital in Aberdeen and the University of Leeds. iPAM is a robotic system which increases the opportunities for stroke patients to exercise their stroke affected upper limbs between their conventional therapy sessions.

One of the sponsors of the Genesis Awards is SchwartzMSL, a leading communications company and Co-CEO Richard Hayhurst commented: "This is a great initiative from One Nucleus and I am delighted to see so many of our fellow service providers having also pledged support. Over the years we have worked with lots of innovative companies and want to help ensure the "UK pipeline" continues to flow in these difficult times."

Ends

Contact Details

Harriet Fear

CEO

Email: harriet@onenucleus.com

Tel: +44 (0)1223 896450

About One Nucleus

Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 450 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers.

Website: www.onenucleus.com

About Genesis

Genesis is an annual must attend conference, exhibition and networking forum in the heart of one of the World's most accessible and effective deal-making locations.

Highlights from Genesis 2011:

- High level **plenary session** followed by very targeted **parallel streams** for biopharma and med tech
- The **UKTI International Zone 1-2-1 partnering facility**. With UKTI bringing in overseas delegates from more than 15 countries, the online partnering system allowed delegates to pre-schedule their 1-2-1 meetings with overseas buyers, partners and trade support experts as well as with all other Genesis delegates. 15 minute appointments were scheduled through the day, thus maximising the effectiveness of the partnering system with the efficiency of the conference buzz. Over 1000 meetings took place
- The **ABCEurope Technology Showcase on Infection & Immunity** European researchers from academia and SMEs presented their innovative technologies in the field of infectious diseases and immunity which are available for licensing or collaborative research projects
- First-class **exhibition area** featured more than 60 UK and overseas exhibitors
- Gala awards dinner celebrated success in 2011

With special thanks to High Q for sponsoring the awards and to the supporting companies who have pledged their assistance to the Award winners:

- Schwartz MSL
- Cambridge Healthcare & Biotech (CH&B)
- PHASTAR
- Global Regulatory Services
- EBD Group
- Edwards Wildman
- Alacrita Consulting
- Stratagem Intellectual Property Management Ltd